[Comment] Treatment of MSSA bacteraemia: a call for a personalised approach

Staphylococcus aureus infections remain a formidable health threat, responsible for the most infection-related deaths worldwide and a mortality rate of up to 30%, despite contemporary infection prevention practices, antimicrobial stewardship, and novel antibiotics.1,2 Treatment of S aureus bacteraemia is often complicated by the inability to remove foreign materials (eg, intravascular devices or osteoarticular hardware) and the development of metastatic foci of infection related to persistent bacteraemia.